Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)

Go to Funding Search

Key Information

Due Date: January 7, 2027


Agency: U.S. Department of Health and Human Services (HHS)


Source: Federal


Funding Category:

Health & Human Services

Funding Amount: Not Specified


Funding Type: Grant, Government


Match Required: No


Contact Info: grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

Overview

This grant, titled "Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)", has two main objectives. The first aim is to support preclinical and patient-centered research that investigates the ways in which incretin mimetics influence cancer risk. Incretin mimetics include agonists or antagonists of GLP-1, GIP-1, as well as dual GLP-1/GIP-1 agents.

The second aim is to attract skilled scientists who can explore the dynamic changes caused by these agents. The focus is to unravel how these agents affect cancer risk beyond short-term outcomes like weight loss and diabetes.

Current data suggests these agents might have a dual effect: increasing the risk of certain obesity-linked cancers while reducing the risk of others. The grant is structured to further this research and deepen our understanding of these impacts.

Show More

Key Dates

Open Date: August 24, 2023


Application Due Date: January 7, 2027


Estimated Award Date: Not Specified

Additional Details

Eligible Activities

  • Research and Development

Eligible Applicants

  • State governments
  • County governments
  • City, village or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Private institutions of higher education
  • Small businesses

Search MI Funding Hub

NOTE: Site search does not include grant search. See Find Funding page for grant searching.